Human Insulin Market Size Worth USD 21.92 Billion in 2032 | Emergen Research

The global human insulin market size was USD 18.17 Billion in 2022 and is expected to register a rapid revenue CAGR of 1.9% during the forecast period. The global human insulin market is poised for substantial expansion, driven by key factors such as the rapid growth of healthcare industries, increasing prevalence of chronic diseases, particularly diabetes, and a surge in Research & Development (R&D) activities alongside government investments.

Market Drivers

Diabetes, the fastest-growing chronic disease worldwide, has seen a steady rise in prevalence over the years, with an estimated 537 million adults affected globally in 2021, according to the World Health Organization (WHO). Moreover, the aging population, expected to double over the next three decades, further contributes to the escalating demand for human insulins.

Technological advancements, notably in recombinant DNA technology and the integration of Artificial Intelligence (AI) into production systems, are also driving market growth. These innovations enhance productivity, energy efficiency, and sustainability, consequently improving customer experience.

To Receive A PDF Sample Of The Report, Visit @https://www.emergenresearch.com/request-sample/2843

Continuous Glucose Monitoring (CGM) devices and insulin pumps represent additional technical breakthroughs revolutionizing insulin therapy. CGM devices enable real-time glucose monitoring, offering valuable insights for effective diabetes management. Similarly, insulin pumps provide precise insulin delivery, enhancing glycemic control and patient convenience.

Market Restraints

The certain factors pose challenges to market growth. Limitations in skilled workforce, high manufacturing expenses, and stringent government regulations may hinder revenue expansion. The considerable costs associated with insulin production equipment and the scarcity of proficient professionals in the field present affordability and operational constraints for manufacturers.

The global human insulin market is segmented based on product, application, and end-use. The dominance of the long-acting insulin segment is attributed to its sustained efficacy and patent protection, accounting for the largest market share in 2022. Biosimilar insulins are anticipated to register moderate growth, driven by their potential to improve patient compliance and reduce drug costs.

In terms of application, the type 1 diabetes segment is expected to hold a significant market share due to the high insulin dependency of type 1 patients, characterized as a more severe condition compared to type 2 diabetes. Conversely, the type 2 diabetes segment is projected to exhibit steady growth, fueled by the rising prevalence of the disease.

Additionally, ongoing Research & Development (R&D) efforts focus on oral insulin delivery systems, offering an alternative to insulin injections. Currently, only two systems have received FDA approval, with ORMD-0801 undergoing phase 3 clinical trials. The approval of such products presents patients with additional treatment options and enhances accessibility to insulin therapy.

To Get A Discount On The Latest Report, Visit @https://www.emergenresearch.com/request-discount/2843

In terms of end-use, the retail pharmacy segment is anticipated to dominate the market, driven by the increased accessibility of treatment options and medications. Patients find it easier to access prescribed medications and related products at local pharmacies, driving demand for these services.

Overall, the global human insulin market is on a trajectory of significant growth, propelled by the escalating prevalence of diabetes, technological advancements, and expanding treatment options. Despite challenges, the market is poised to witness substantial expansion in the coming years.

Human Insulin Top Companies and Competitive Landscape

The global human insulin market is fairly fragmented with many large and medium-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective human insulin solutions.

• Tonghua Dongbao Pharmaceutical Co., Ltd.
• Eli Lilly and Company
• Biocon Ltd.
• Merck & Co., Inc.
• Ypsomed AG
• Johnson & Johnson Private Limited
• Albireo Pharma, Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• WOCKHARDT

Human Insulin Latest Industry News

• In November 2022, Biocon Sdn. Bhd., a subsidiary of Biocon based in Malaysia, disclosed the acquisition of a three-year contract for its recombinant human insulin brand, Insugen, awarded by the Ministry of Health (MoH) in Malaysia.

Browse Detailed Research Report @https://www.emergenresearch.com/industry-report/human-insulin-market

Human Insulin Market Segment Analysis

For the purpose of this report, Emergen Research has segmented the global human insulin market on the basis of product, application, type, end-use, and region:

• Product Outlook (Revenue, USD Billion; 2019-2032)
o Rapid acting insulin
o Long acting insulin
o Combination insulin
o Biosimilar insulin
o Others

• Application Outlook (Revenue, USD Billion; 2019-2032)
o Type 1
o Type 2

• Type Outlook (Revenue, USD Billion; 2019-2032)
o Analog insulin
o Human insulin

• End-Use Outlook (Revenue, USD Billion; 2019-2032)
o Hospital & clinics
o Retail pharmacy
o Others

• Regional Outlook (Revenue, USD Billion; 2019-2032)
o North America
1. U.S.
2. Canada
o Europe
1. Germany
2. France
3. UK
4. Italy
5. Spain
6. Benelux
7. Russia
8. Rest of Europe
o Asia Pacific
1. China
2. Japan
3. South Korea
4. India
5. ASEAN Countries
6. Oceania
7. Rest of APAC
o Latin America
1. Brazil
2. Mexico
3. Rest of LATAM
o Middle East & Africa
1. GCC Countries
2. Israel
3. Turkey
4. South Africa
5. Rest of Middle East & Africa

Buy Now: @https://www.emergenresearch.com/select-license/2843

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

This release was published on openPR.